# DESCRIPTION

## FIELD OF THE INVENTION

- introduce fields of medicine and drug discovery

## BACKGROUND

- describe brain and CNS diseases
- discuss limitations of current treatments
- motivate need for novel delivery methods

## SUMMARY

- introduce cyclic peptides and conjugates
- describe compositions and kits
- outline methods for intranasal delivery
- specify treatment of neurological diseases
- detail Odorranalectin (OL) sequence
- describe fucose binding site
- outline grafting and conjugating strategies
- discuss experimental results
- describe cyclic peptide of general Formula I
- outline cyclic peptide conjugate
- describe composition including cyclic peptide
- detail combinatorial library
- outline method of identifying opioid cyclic peptides
- describe method of treating neurological disorders

## DETAILED DESCRIPTION

- introduce novel cyclic peptides and conjugates for treating neurological diseases
- describe intranasal delivery and combinatorial libraries for identifying therapeutic agents

### Cyclic Peptides, Cyclic Peptide Conjugates, and Compositions for Treating Neurological Diseases, Disorders and Disabling Conditions

- define cyclic peptides and conjugates with biologically active peptides or proteins
- describe general Formula 1 for cyclic peptides
- detail Xm, X1, X2, and X3 components of Formula 1
- provide examples of biologically active peptides or proteins
- describe opioid receptor ligands and agonists/antagonists
- give examples of cyclic peptides with opioid receptor ligands
- introduce therapeutic agents conjugated to cyclic peptides
- describe click reactions for conjugating therapeutic agents
- provide examples of small molecule conjugation to OL
- describe compositions for treating neurological diseases
- introduce additional therapeutic agents for synergistic effects
- describe target cells in the CNS
- outline delivery methods for cyclic peptides and conjugates

### Cyclic Peptide Combinatorial Libraries and Methods of Use Thereof

- introduce combinatorial libraries of cyclic peptides
- describe generation of positional-scanning synthetic combinatorial library
- outline methods for making combinatorial libraries
- describe Formula 1 and Formula II for cyclic peptides in libraries
- outline screening methods for identifying ligands for receptors of interest
- describe assays for testing affinity, selectivity, and activity of opioid cyclic peptides

### Methods of Treating Neurological Diseases, Disorders, and Disabling Conditions in an Individual in Need Thereof

- define treatment methods
- describe administration routes
- motivate combination therapy
- describe pharmaceutical formulations
- determine effective doses
- describe kit components
- outline instructional materials
- specify kit packaging

## EXAMPLES

- illustrate the invention with specific examples

### Example 1—Novel Cyclic Peptide-Based Platform for Intranasal Drug Delivery to the Brain

- introduce the problem of delivering therapeutic agents to the brain
- describe the utility of the cyclic peptide-based platform for i.n. drug delivery to the brain
- synthesize individual peptides
- perform binding studies
- evaluate in vivo activity
- demonstrate antinociceptive effects
- show no impairment in motor coordination
- prepare and test TIPP-OL analogue
- prepare and test bifunctional OL analogue TIPP-EM1-OL
- optimize OL-based opioid ligands
- validate the approach and identify novel opioid ligands

### Example 2—Additional Cyclic Compounds and Use Thereof

- modify the N-terminal part of OL
- prepare and test DADLE-OL II
- identify novel cyclic peptide opioid ligands
- describe the benefits of KOR agonists
- prepare and screen an OL-based PSCL
- identify novel MOR agonist OLMOR-L1
- evaluate the analgesic activity of OLMOR-L1
- identify novel OL-based KOR ligand OLKOR-L1
- evaluate the analgesic activity of OLKOR-L1
- prepare and test OLKOR-L1 analogue with 5-HTrp
- analyze the brain accumulation of OLKOR-L1-5HTrp

### Other Embodiments

- disclaim limitations

